Program Director within the Division of Neuroscience and Behavior at the National Institute on Drug Abuse (NIDA)
Dr. Kristopher Bough is a Program Director within the Division of Neuroscience and Behavior at the National Institute on Drug Abuse (NIDA). He manages a diverse portfolio of Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR), and research project grant awards focused on early translational technologies. Prior to the joining the NIH | NIDA, Dr. Bough worked as a primary drug reviewer of abbreviated new drug applications within the FDA’s Center for Drug Evaluation and Research (2005-2008) and as a neuroscience researcher (2001-2005). Dr. Bough has a B.S. degree in Biology from Gettysburg College and M.S. and Ph.D. degrees in Biology (neuroscience) from Georgetown University.
This session will be led by the NIH Center for Scientific Review, the SBIR/STTR Peer Review Mock Study Section will give you a chance to see a small business peer review study section meeting in action. You will hear frequent questions asked by reviewers and learn mistakes that small business applicants often make. This session […]
The SBIR funding mechanism is unique in many ways. But it is the only mechanism that “requires” post-funding actions. Publications, graduate course and thesis completion, and training events or curricula may be expected from other NIH grant mechanisms. Meanwhile, SBIR funds Phases I and II but has built into the funding mechanism a Phase III […]
During this session attendees will learn about various NIH and external resources available to small businesses and entrepreneurs. The National Center for Advancing Translational Sciences (NCATS) and National Institute on Drug Abuse (NIDA) will discuss its grant programs, resources and in-kind services/programs designed to support the transformation of scientific knowledge into better human health. NCATS […]
NIH has a number of new initiatives focused on specific areas in neurology, including research in Alzheimer’s Disease, pain and opioid addition, as well as new technologies for researchers. Come hear about the Alzheimer’s Disease and AD-Related Dementias (AD/ADRD), Helping to End Addition Long-term (HEAL) Initiatives, and Brain Research through Advancing Innovative Neurotechnologies (BRAIN).